Overview
Casdin Capital is a venture investor focused on funding next-generation life science innovation. It finances early-stage and growth-stage biotech companies, particularly in areas like gene therapy, cancer, rare diseases, and industrial biotechnology, to help bring new therapies and biotechnologies to market. Its product is capital and strategic support for life science startups; as investors, they provide funding, guidance, and connections to advance scientific breakthroughs into products. Casdin differentiates itself by concentrating on cutting-edge biology and genome-focused therapies, leveraging expertise in biotechnology and policy to guide portfolio companies and navigate regulatory and market landscapes. The company’s goal is to accelerate the development and commercialization of transformative biotechnologies that can improve health and biotech outcomes.
Work here?Claim your company
Simplify's take
What believers are saying
- Casdin stayed active in 2026, backing Atrium Therapeutics, Multiply Labs, and Flare.
- Dealroom logged 216 investments and 75 exits, signaling enduring sourcing and liquidity.
- Casdin kept buying GeneDx in June 2026 despite a 67% stock collapse.
What critics are saying
- Casdin’s identity depends on Eli Casdin; succession risk is immediate and existential.
- GeneDx exposure creates conflicts and headline risk when portfolio company stock swings sharply.
- Biotech concentration leaves Casdin exposed if 2026-2027 financing markets shut and exits stall.
What makes Casdin Capital unique
- Eli Casdin blends hedge-fund trading with venture investing across genomics, oncology, and tools.
- Casdin’s board access shows up in GeneDx, where Eli Casdin joined since 2021.
- The firm repeatedly backs platform biology companies, not generic software or healthcare services.
Help us improve and share your feedback! Did you find this helpful?